AbbVie Inc. (ABBV) Thursday announced positive results from SELECT-GCA Phase 3 of Upadacitinib 15 mg, once daily in combination with a 26-week steroid taper regimen in adults with giant cell arteritis.
The pharma company said its randomized, double-blind, placebo-controlled study achieved primary endpoint of sustained remission.
The study results showed that 46 percent of patients receiving Upadacitinib 15 mg in combination, achieved sustained remission compared to 29 percent of patients receiving placebo.
Giant cell arteritis, also known as temporal arteritis, is an autoimmune disease that causes inflammation of the temporal and other cranial arteries, the aorta, and other large and medium arteries.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.